These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32067683)

  • 1. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
    Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
    Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
    Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
    Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
    Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
    Hainsworth JD; Meric-Bernstam F; Swanton C; Hurwitz H; Spigel DR; Sweeney C; Burris H; Bose R; Yoo B; Stein A; Beattie M; Kurzrock R
    J Clin Oncol; 2018 Feb; 36(6):536-542. PubMed ID: 29320312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
    Sweeney CJ; Hainsworth JD; Bose R; Burris HA; Kurzrock R; Swanton C; Friedman CF; Spigel DR; Szado T; Schulze K; Price R; Malato J; Lo AA; Levy J; Wang Y; Yu W; Meric-Bernstam F
    J Clin Oncol; 2024 Jan; 42(3):258-265. PubMed ID: 37793085
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
    Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
    Wotman M; El-Naggar A; Ferrarotto R
    Expert Rev Anticancer Ther; 2023 Jun; 23(6):573-582. PubMed ID: 37114470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
    Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
    Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
    ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring
    Mazieres J; Lafitte C; Ricordel C; Greillier L; Negre E; Zalcman G; Domblides C; Madelaine J; Bennouna J; Mascaux C; Moro-Sibilot D; Pinquie F; Cortot AB; Otto J; Cadranel J; Langlais A; Morin F; Westeel V; Besse B
    J Clin Oncol; 2022 Mar; 40(7):719-728. PubMed ID: 35073148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies.
    Takahashi S; Bando H; Kinoshita I; Modi S; Tsurutani J; Bang YJ; Sato Y; Nakatani S; Lee C; Sugihara M; Okuda Y; Iwata H
    Jpn J Clin Oncol; 2024 Apr; 54(4):434-443. PubMed ID: 38231777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial).
    Takahashi K; Ishibashi E; Kubo T; Harada Y; Hayashi H; Kano M; Shimizu Y; Shirota H; Mori Y; Muto M; Ishioka C; Dosaka-Akita H; Matsubara H; Nishihara H; Sueoka-Aragane N; Toyooka S; Hirakawa A; Tateishi U; Miyake S; Ikeda S
    Medicine (Baltimore); 2020 Aug; 99(32):e21457. PubMed ID: 32769873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers.
    Haigh JE; Patel K; Rack S; Jiménez-Labaig P; Betts G; Harrington KJ; Metcalf R
    Curr Oncol; 2024 Sep; 31(9):5652-5661. PubMed ID: 39330047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
    Yamamoto Y; Iwata H; Taira N; Masuda N; Takahashi M; Yoshinami T; Ueno T; Toyama T; Yamanaka T; Takano T; Kashiwaba M; Tsugawa K; Hasegawa Y; Tamura K; Tada H; Hara F; Fujisawa T; Niikura N; Saji S; Morita S; Toi M; Ohno S
    Cancer Sci; 2022 Sep; 113(9):3169-3179. PubMed ID: 35754298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
    Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.